ELDN - eledon.com Market Capitalization
Eledon Pharmaceuticals (ELDN) develops methods to protect transplanted organs by utilizing safe molecules to suppress the immune response. The current strategy relies on finding a major partner to bring its lead product to market, as there are no funds available for acquisitions. This chart illustrating the price evolution of the stock, where the market capitalization stands at 0.17, confirms the company's status as a developer of targeted antibodies to combat ALS and tissue rejection.
Comprehensive metric breakdowns and analytics for Eledon Pharmaceuticals, Inc (ELDN)
- market price and analyst price targets:
- market capitalization statistics:
- issuer book value statistics:
- company total debt and liquidity indicators:
Total Debt to Capital Eledon Pharmaceuticals|ELDN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Eledon Pharmaceuticals|ELDN - Company Aggregate Debts|Debt to Book Capitalization Ratio Eledon Pharmaceuticals, Inc|ELDN - Company Long-Term Loans and Borrowings|Company Short-Term Debt Eledon Pharmaceuticals|Quick Ratio eledon.com
- business earnings and investment ratios data:
ELDN - Net Profit|Future Profit Eledon Pharmaceuticals|ELDN - Company Value to Net Income|Forward P/E Multiple Eledon|ELDN - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eledon Pharmaceuticals, Inc|ELDN - Operating profit before deduction of amortization|Earnings per share for the last twelve months Eledon Pharmaceuticals|ELDN - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months eledon.com|ELDN - Earnings growth in current year|Net earnings per share growth forecast for next year Eledon Pharmaceuticals
- sales and revenue indicators:
Fundamental company analysis:ELDN (Eledon Pharmaceuticals, Inc.)
Eledon Pharmaceuticals (ELDN) is a specialized biotech asset with a limited scale of operations. The issuer's total market capitalization is calculated as the product of the current share price and the total number of outstanding shares. This indicator determines the market value of the business and its compliance with index criteria. The trend in the issuer's total market capitalization reflects market expectations regarding the success of the drug tegoprubart. A low capital base increases the potential for returns upon confirmation of the therapy's efficacy.
Key competitors
Market Value argenx ARGX|BioNTech Inc. - Market Value|Abivax S.A. - Market Capitalization|ADMA (ADMA Corp) - Market Capitalization|Protagonist Therapeutics (PTGX) - Market Value|Market Capitalization IMVT|Market Value Kiniksa|Grifols SA - Market Valuation|Market Capitalization ADPT|CLDX (Celldex Corp) - Market Value|Market Capitalization AUPH (Aurinia Pharmaceuticals)|Market Capitalization biocryst.com BCRX|VERA - Market Value|Market Value DNTH (Dianthus Therapeutics Inc)|Pharvaris Corp (PHVS) - Market Value|Market Valuation AbCellera Biologics Inc.|TRML (Tourmaline Bio, Inc.) - Market Capitalization|Market Capitalization precigen.com|Market Valuation PHAR (Pharming Group)|NKTR (Nektar Therapeutics Inc) - Market Value|Market Capitalization UPB (Upstream Bio Corp)|Market Capitalization Zenas Corp (ZBIO)|IMNM - Market Value|gossamerbio.com (GOSS) - Market Valuation|KalVista Pharmaceuticals, Inc. (KALV) - Market Value|Market Valuation Septerna, Inc.|Market Valuation PVLA|Market Capitalization Savara Pharma|Market Value Rigel Pharmaceuticals (RIGL)|anaptysbio.com - Market Capitalization|Market Capitalization ATXS (Astria Therapeutics, Inc.)|enGene Holdings Inc (ENGN) - Market Value|RAPT Therapeutics - Market Capitalization|Market Value Aerovate Therapeutics Inc|Aclaris Therapeutics (ACRS) - Market Value|KYTX (kyvernatx.com) - Market Value|TLSA (Tiziana Life Sciences Ltd) - Market Capitalization|Market Value Cabaletta Bio Inc. CABA|Market Capitalization VTYX|Theratechnologies, Inc - Market Capitalization|Market Value Avalo Therapeutics, Inc AVTX|agenusbio.com (AGEN) - Market Value|CLYM - Market Value|ZURA (zurabio.com) - Market Capitalization|ATYR (aTyr) - Market Valuation|Adagene Inc. - Market Value|Market Value ImageneBio|Shattuck Therapeutics - Market Valuation|Market Capitalization EQ|CNTB (connectbiopharm.com) - Market Value|Market Capitalization IMUX (Immunic)|Market Capitalization Atara Biotherapeutics, Inc. ATRA|IFRX - Market Value|Market Value XFOR (x4pharma.com)|adicetbio.com (ACET) - Market Value|Market Valuation Celularity|INMB (INmune Bio Corp) - Market Capitalization|Market Capitalization Barinthus Biotherapeutics Corp|Market Capitalization KZR|Market Valuation sabbiotherapeutics.com SABS|Market Capitalization AKTX (Akari Therapeutics Plc)|Enlivex Therapeutics Ltd (ENLV) - Market Value|QTTB: Market Valuation|GOVX - Market Capitalization|EDSA (Edesa Biotech, Inc.) - Market Valuation|IBIO: Market Value|CARM (Carisma Therapeutics Inc) - Market Capitalization|XTL Biopharmaceuticals Ltd (XTLB) - Market Capitalization|Market Capitalization BOLT|Market Valuation hcwbiologics.com HCWB|Market Capitalization APVO (Aptevo Therapeutics Inc.)|Market Capitalization aimimmuno.com AIM|ADTX - Market Value|GRI: Market Value|XORTX (XRTX) - Market Value|HIND - Market Capitalization|REVB (Revelation Biosciences) - Market Capitalization|Market Value indaptusrx.com INDP|Market Value Scinai Immunotherapeutics Ltd. (SCNI)|Market Value CALI (calcimedica.com)|Market Capitalization AFMD (Affimed N.V.)|ALLK: Market Capitalization|HOOK - Market Value|IGMS (IGM Biosciences, Inc.) - Market Capitalization|iTeos Therapeutics, Inc. (ITOS) - Market Value|Market Valuation OCEA (Ocean Biomedical Inc)|TCBP (TC BioPharm (Holdings) PLC) - Market Capitalization|THRD: Market Value
